Download this short summary slideset of key takeaways from a live CCO Webinar focused on the use of PARP inhibitors in prostate cancer, including guidance on genetic testing for DNA repair defects.
Get up to date on how PARP inhibitors target tumor cells with DNA repair deficiencies as well as germline and somatic testing in patients with prostate cancer.
Get up to date on the use of newly approved and emerging PARP inhibitors for the treatment of patients with metastatic CRPC and DNA repair defects. Includes a case study!
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.